Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSEAM:GROY
NYSEAM:GROYMetals and Mining

Gold Royalty (GROY) Valuation After Borborema Royalty Deal And Record Preliminary Revenue

Gold Royalty (GROY) has been in focus after reporting preliminary revenue of US$4,501,000 for the quarter and US$15,610,000 for 2025, alongside acquiring a net smelter royalty on Brazil’s Borborema gold mine. See our latest analysis for Gold Royalty. At a share price of US$4.65, Gold Royalty has seen a 26.02% 90 day share price return and a very large 263.28% 1 year total shareholder return. This suggests recent momentum that contrasts with the 1 day and 7 day pullback, as the market weighs...
NasdaqGS:TRMB
NasdaqGS:TRMBSoftware

Trimble’s New Midwest Outlet Partnership And What It Means For Valuation

Trimble (NasdaqGS:TRMB) has appointed West Side Tractor Sales Co. as its newest Trimble Technology Outlet. The partnership focuses on civil construction customers using John Deere earthmoving equipment. The agreement covers northern Illinois, Indiana, and parts of Michigan. Customers in these territories gain broader access to Trimble grade control and site positioning solutions. For you as an investor looking at Trimble, this move fits within its core role providing technology for civil...
NasdaqGM:NTLA
NasdaqGM:NTLABiotechs

Why Intellia Therapeutics (NTLA) Is Down 12.6% After FDA Lifts Hold On Key CRISPR Trial

In late January 2026, Intellia Therapeutics announced that the FDA removed the clinical hold on its MAGNITUDE-2 Phase 3 trial of CRISPR-based therapy nexiguran ziclumeran for hereditary transthyretin amyloidosis with polyneuropathy, allowing patient enrollment and dosing to resume under enhanced liver safety monitoring and a slightly expanded enrollment target. This decision marks a key regulatory step for Intellia’s in vivo gene-editing program, highlighting both the promise of a one-time...
NYSE:NEM
NYSE:NEMMetals and Mining

How Investors Are Reacting To Newmont (NEM) Surging With Record Gold Prices And Portfolio Streamlining

In late January 2026, Newmont benefited from record-breaking gold and silver prices driven by geopolitical tensions, economic uncertainty, and strong central bank demand, alongside fresh operational updates at the AME Roundup conference in Vancouver. Together with streamlining after the Newcrest acquisition and plans to sell millions of ounces from core mines, these conditions have sharpened Newmont’s role as a key proxy for safe-haven precious metals exposure. We’ll now examine how this mix...
SWX:ADEN
SWX:ADENProfessional Services

Adecco Expands Healthcare Reach With Advantis Deal And Valuation Discount

Adecco Group (SWX:ADEN) has agreed to acquire Advantis Medical Staffing. The deal expands Adecco’s presence in North American healthcare staffing. Advantis adds travel nursing and allied health capabilities to Adecco’s portfolio. The acquisition focuses Adecco more on healthcare as a critical talent segment. Adecco Group, a global provider of HR and workforce solutions, is deepening its focus on healthcare staffing through the purchase of Advantis Medical Staffing. Advantis brings a...
ASX:PRU
ASX:PRUMetals and Mining

A Look At Perseus Mining’s Valuation As Production Guidance For 2026 Is Reaffirmed

Perseus Mining (ASX:PRU) has drawn fresh attention after reporting December 2025 quarter production of 78,641 ounces of gold at All In Site Costs of $1,800 per ounce and reaffirming its 2026 output guidance. See our latest analysis for Perseus Mining. The reaffirmed 2026 production guidance and progress at CMA Underground and Nyanzaga come as Perseus Mining’s share price sits at A$5.90, with a 21.15% 90 day share price return and a 5 year total shareholder return of 449.64%. This indicates...
NYSE:SE
NYSE:SEMultiline Retail

Sea Prioritizes Growth Investments As Valuation Signals Potential Upside

Sea Limited (NYSE:SE) recently reported quarterly results that highlighted strong revenue and gross merchandise value performance. Management chose to prioritize growth initiatives in logistics, fulfillment, and membership programs, even though these moves weigh on near term margins. The company signaled an intention to keep funding these initiatives as it refines its business model and competitive position. Sea runs a broad digital ecosystem across e commerce, digital entertainment, and...
ENXTPA:SPIE
ENXTPA:SPIECommercial Services

SPIE (ENXTPA:SPIE) Valuation Check After AI Hub Rollout And Dutch Grid Modernisation Deal

SPIE (ENXTPA:SPIE) is in focus after two fresh company updates: the rollout of its AI Hub across French subsidiaries, and a long term grid modernisation agreement in the Utrecht West region. See our latest analysis for SPIE. At a share price of €46.7, SPIE has seen a 5.85% 90 day share price return while its 1 year total shareholder return of 50.56% points to momentum that has been building over a longer horizon. The recent AI Hub rollout and Dutch grid contract help to frame the current mood...
BME:HOME
BME:HOMEConsumer Durables

Assessing Neinor Homes (BME:HOME) Valuation After Recent Share Price Momentum

Neinor Homes (BME:HOME) has drawn investor interest after recent share price gains over the past month and the past 3 months, prompting a closer look at how its current valuation lines up with fundamentals. See our latest analysis for Neinor Homes. Those near term share price returns of 1.8% over one day and 7.2% over 30 days sit alongside a 16.7% 90 day share price return and a 30% one year total shareholder return. Together, these point to building momentum around the €20.15 share price. If...
NYSE:LLY
NYSE:LLYPharmaceuticals

Eli Lilly Extends Beyond GLP 1 With Gene Editing And Cancer Push

Eli Lilly (NYSE:LLY) agreed to work with Seamless Therapeutics on gene editing therapies for hearing loss. The company entered a research agreement with Repertoire Immune Medicines to pursue tolerizing therapies for autoimmune diseases. The FDA granted Breakthrough Therapy designation to oncology candidate sofetabart mipitecan for platinum resistant ovarian cancer. Eli Lilly, long known for its diabetes and obesity franchises, is pushing further into genetic medicines and oncology as it...